<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00625456</url>
  </required_header>
  <id_info>
    <org_study_id>JX594-IV-011</org_study_id>
    <nct_id>NCT00625456</nct_id>
  </id_info>
  <brief_title>Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors</brief_title>
  <official_title>A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jennerex Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SillaJen, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, open-label, dose-escalation trial in patients with advanced/metastatic&#xD;
      solid tumors refractory to standard therapy; tumors may include malignant melanoma, non-small&#xD;
      cell lung cancer, renal cell carcinoma, and squamous cell carcinoma of the head and neck.&#xD;
      These tumor types were selected because evidence of biological activity was observed in these&#xD;
      tumor types in a Phase I study of JX-594 (Pexa-Vec) administered by intratumoral injection in&#xD;
      patients with metastatic disease to the liver. Patients will receive treatment at one of five&#xD;
      dose levels in a sequential dose-escalating design.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximally-tolerated dose (MTD) and/or maximum-feasible dose (MFD) of JX-594 administered by intravenous (IV) infusion</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety/Toxicity: Incidence of treatment-related adverse events; treatment-related serious adverse events; treatment-related Grade 3/4 toxicities; and clinically-significant, treatment-related changes from baseline in routine laboratory parameters</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the JX-594 pharmacokinetics and pharmacodynamics over time following IV infusion</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the immune response to JX-594 following IV infusion</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the delivery of JX-594 to, and concentration within, solid tumors following IV infusion</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Melanoma</condition>
  <condition>Lung Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Single Arm, dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation starting dose 1e5 pfu/kg bw to 3e7 pfu/kg bw; Recombinant Vaccinia GM-CSF (JX-594)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)</intervention_name>
    <description>Intravenous Dosage from 1 x 10^5 pfu/kg to 3 x 10^7 pfu/kg Intravenous infusion is administered once over a 60 minute period</description>
    <arm_group_label>Single Arm, dose escalation</arm_group_label>
    <other_name>JX-594</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically-confirmed, advanced/metastatic solid tumor refractory to standard&#xD;
             therapy or the patient has refused or does not tolerate the standard therapy; tumors&#xD;
             may include malignant melanoma, non-small cell lung cancer, renal cell carcinoma, and&#xD;
             squamous cell carcinoma of the head and neck&#xD;
&#xD;
          -  At least one measurable tumor mass by CT/MRI (i.e. lesion that can accurately be&#xD;
             measured in at least one dimension with longest diameter &gt; 1 cm)&#xD;
&#xD;
          -  At least one tumor mass amenable to biopsy and/or FNA&#xD;
&#xD;
          -  Expected survival for approximately 16 weeks or longer&#xD;
&#xD;
          -  Karnofsky Performance Score (KPS) ≥ 70&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  WBC ≥ 3,500 cells/mm3 and ≤ 50,000 cells/mm3&#xD;
&#xD;
          -  ANC ≥ 1,500 cells/mm3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 100,000 plts/mm3&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
          -  AST, ALT ≤ 2.5 x ULN&#xD;
&#xD;
          -  Serum chemistries within normal limits (WNL) or Grade 1 - If patients are diabetic or&#xD;
             have a screening random glucose &gt; 160 mg/dL, a fasting glucose must be done and&#xD;
             patients must be WNL or Grade 1 in order to be eligible for the study.&#xD;
&#xD;
          -  Acceptable coagulation status: INR ≤ (ULN + 10%)&#xD;
&#xD;
          -  CD4 count ≥ 500/mm3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant immunodeficiency due to underlying illness (e.g. HIV/AIDS) and/or&#xD;
             medication (e.g. systemic corticosteroids)&#xD;
&#xD;
          -  Known myeloproliferative disorders requiring systemic therapy&#xD;
&#xD;
          -  History of exfoliative skin condition (e.g. eczema or ectopic dermatitis) requiring&#xD;
             systemic therapy&#xD;
&#xD;
          -  Tumor(s) invading a major vascular structure (e.g. carotid artery)&#xD;
&#xD;
          -  Tumor(s) in location that would potentially result in significant clinical adverse&#xD;
             effects if post-treatment tumor swelling were to occur (e.g. tumors impinging on the&#xD;
             upper airway or affecting biliary tract drainage, etc.)&#xD;
&#xD;
          -  Clinically significant and/or rapidly accumulating ascites, peri-cardial and/or&#xD;
             pleural effusions&#xD;
&#xD;
          -  Severe or unstable cardiac disease&#xD;
&#xD;
          -  Current, known CNS malignancy (history of completely resected or irradiated brain&#xD;
             metastases allowed)&#xD;
&#xD;
          -  Received anti-cancer therapy within 4 weeks prior to first treatment (6 weeks in case&#xD;
             of mitomycin C or nitrosoureas)&#xD;
&#xD;
          -  Use of anti-viral, anti-platelet, or anti-coagulation medication [Patients who&#xD;
             discontinue such medications within 7 days prior to first treatment may be eligible&#xD;
             for this study.]&#xD;
&#xD;
          -  Pulse oximetry O2 saturation &lt;90% at rest&#xD;
&#xD;
          -  Experienced a severe systemic reaction or side-effect as a result of a previous&#xD;
             smallpox vaccination&#xD;
&#xD;
        Household contact exclusions:&#xD;
&#xD;
          -  Women who are pregnant or nursing an infant&#xD;
&#xD;
          -  Children &lt; 5 years old&#xD;
&#xD;
          -  History of exfoliative skin condition (e.g. eczema) that at some stage has required&#xD;
             systemic therapy&#xD;
&#xD;
          -  Significant immunodeficiency due to underlying illness (e.g. HIV/AIDS) and/or&#xD;
             medication (e.g. systemic corticosteroids)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Kirn, MD</last_name>
    <role>Study Director</role>
    <affiliation>Jennerex Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Billings Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Health Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>February 19, 2008</study_first_submitted>
  <study_first_submitted_qc>February 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2008</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>phase I</keyword>
  <keyword>advanced metastatic solid tumors</keyword>
  <keyword>oncolytic virus</keyword>
  <keyword>vaccinia virus</keyword>
  <keyword>melanoma</keyword>
  <keyword>lung cancer</keyword>
  <keyword>renal cell carcinoma</keyword>
  <keyword>squamous cell carcinoma of the head and neck</keyword>
  <keyword>Pexa-Vec</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccinia</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molgramostim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

